The laboratory team is committed to provide cutting edge genome research in hematology and oncology with a specific focus on characterization of hematological malignancies and hereditary cancer risk aimed to provide the molecular bases for cancer prevention and for precision medicine.
Director: Prof. Enrico Tagliafico
Principal Investigators: Prof. Enrico Tagliafico, Prof. Elena Tenedini
Lab units
Two units work in the group: the first (P.I. Prof Enrico Tagliafico) is specifically dedicated to the genomic characterization of haematological neoplasms, the second (P.I. Prof. Elena Tenedini) is focused on hereditary cancer
Research lines
The research group are currently focused on the genomics of Acute Lymphoblastic Leukemia, on the other hand, is investigating the impact of constitutional mosaicism in the management of patients with hereditary cancer risk
Publications
The researchers of the research group have produced since 1987 more than 200 papers (70 in the five-year period 2020-2025) with a total Impact Factor, since 1987, of more than 1900 and an average Impact Factor of 10.02
Call for collaboration
Fill out the form to propose a collaboration
Selected posts from the world of diagnostic hematology and clinical genomics
Clinical diagnostic DNA sequencing can be used to identify resistance to immunotherapies, allowing for effective treatment management. Read the full article in Blood Advances: https://t.co/r0I4aiehAS pic.twitter.com/9mDl4XYOG6
— Blood Journals Portfolio (@BloodPortfolio) January 26, 2026
According to the Consensus Genomic Staging, 22.4% of patients are classified as high risk (excluding β2-microglobulin criterion). Read in Blood: https://t.co/vJP4feCVTW #MultipleMyeloma #Blood pic.twitter.com/ItmWjlDIC1
— Blood Journals Portfolio (@BloodPortfolio) January 19, 2026
Ivosidenib and venetoclax, with or without azacitidine, either rapidly select resistant leukemic clones or eradicate leukemic clones. Read the plenary paper in Blood: https://t.co/Kt4eGYKe24 #PlenaryPaper #BloodJournal pic.twitter.com/KQu3ufu7ST
— Blood Journals Portfolio (@BloodPortfolio) February 5, 2026
🎥 The recent AML Hub virtual symposium ended with a Q&A session during which Gail Roboz, Jorge Sierra, and Jorge Cortes discussed treatment decisions for patients with FLT3m AML.
Watch the full video here: https://t.co/wK6AHJH3cm#AMLsm #leusm #MedEd pic.twitter.com/JtvK39t0i8
— AML Hub (@AML_Hub) January 28, 2026